Table 2.
Clinical trials of targeting HSP90 ATPase inhibitors
| Name | Adjunctive agents | Conditions | Phase | Status | First Posted | NCT number |
|---|---|---|---|---|---|---|
| 17-AAG | / | ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia | I | Terminated | 2005 | NCT00319930 |
| / |
Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma |
II | Completed | 2005 | NCT00117988 | |
| / | Advanced Solid Tumors or Non-Hodgkin’s Lymphoma | I | Terminated | 2003 | NCT00019708 | |
| / | Relapsed or Refractory Solid Tumors or Leukemia | I | Completed | 2004 | NCT00079404 | |
| Sorafenib tosylate | Unresectable or Metastatic Solid Tumors | I | Completed | 2005 | NCT00121264 | |
| 17-DMAG | / | HER2 Positive Breast Cancer | II | Terminated | 2008 | NCT00780000 |
| / |
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Prolymphocytic Leukemia |
I | Terminated | 2010 | NCT01126502 | |
| Trastuzumab and Paclitaxel | Breast Cancer or Solid Tumor | I | Completed | 2008 | NCT00803556 | |
| IPI-504 | / | Lung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer, | II | Terminated | 2010 | NCT01228435 |
| Docetaxel | Non-small Cell Lung Cancer | II | Completed | 2011 | NCT01362400 | |
| IPI-493 | / | Hematologic Malignancies | I | Terminated | 2010 | NCT01193491 |
| / | Advanced Malignancies | I | Terminated | 2008 | NCT00724425 | |
| AT13387 | / | Solid Tumors, Breast Cancer | I | Completed | 2010 | NCT01246102 |
| / | Metastatic Solid Tumors | I | Completed | 2009 | NCT00878423 | |
| Crizotinib | Non-Small Cell Lung Cancer | I/II | Completed | 2012 | NCT01712217 | |
| Abiraterone Acetate | Prostate Cancer | I/II | Completed | 2012 | NCT01685268 | |
| STA-9090 | / | Solid Tumors | I | Completed | 2008 | NCT00687934 |
| Docetaxel | Solid Tumor Malignancies | I | Completed | 2010 | NCT01183364 | |
| BIIB021 | / | Gastrointestinal Stromal Tumors | II | Completed | 2008 | NCT00618319 |
| / | Advanced Solid Tumors | I | Completed | 2008 | NCT00618735 | |
| Antacid | Advanced Solid Tumors | I | Completed | 2009 | NCT01017198 | |
| Exemestane | Hormone Receptor Positive Metastatic Breast Cancer | II | Completed | 2009 | NCT01004081 | |
| BIIB028 | / | Advanced Solid Tumors | I | Completed | 2008 | NCT00725933 |
| PU-H71 | / |
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis |
I | Terminated | 2019 | NCT03935555 |
| / | Solid Tumors and Low-Grade Non-Hodgkin’s Lymphoma | I | Terminated | 2012 | NCT01581541 | |
| / | PET Imaging of Cancer Patients | Early I | Active, not recruiting | 2011 | NCT01269593 | |
| MPC-3100 | / | Refractory or Relapsed Cancer | I | Completed | 2009 | NCT00920205 |
| Debio 0932 | / | Cancer, Neoplasms, Solid Tumors, Lymphoma | I | Completed | 2010 | NCT01168752 |
| / | Psoriasis Vulgaris | I | Unknown | 2018 | NCT03675542 | |
| XL888 | / | Solid Tumors | I | Terminated | 2008 | NCT00796484 |
| Vemurafenib | Melanoma | I | Completed | 2012 | NCT01657591 | |
| Vemurafenib and Cobimetinib | Melanoma | I | Active, not recruiting | 2016 | NCT02721459 | |
| SNX-5422 | / |
Solid Tumor Malignancy, Lymphoid Malignancy, Leukemia, Lymphoma |
I | Completed | 2008 | NCT00647764 |
| / | Solid Tumor Malignancies | I | Completed | 2007 | NCT00506805 | |
| / | HER2 Positive Cancers. | I/II | Terminated | 2013 | NCT01848756 | |
| Ibrutinib | Chronic lymphocytic leukemia | I | Withdraw | 2016 | NCT02914327 | |
| TAS-116 | Palbociclib | Breast and Rb-null Cancer | I | Recruiting | 2022 | NCT05655598 |
| Imatinib and Sunitinib | Gastrointestinal Stromal Tumors | I | Recruiting | 2022 | NCT05245968 | |
| / | Solid Tumors | I | Completed | 2016 | NCT02965885 | |
| HSP990 | / | Advanced Solid Tumors | I | Terminated | 2010 | NCT01064089 |
| / | Advanced Solid Tumors | I | Completed | 2009 | NCT00879905 |
The results are obtained by searching in clinicaltrials.gov. using different HSP members as keywords. Data were last updated on July 25th, 2024